Alkeus, an unorthodox eye drug startup, acquired by Tarsus for up to $800M

Alkeus, an unorthodox eye drug startup, acquired by Tarsus for up to $800M →

Alkeus brought to late-stage testing a Stargardt disease therapy that former executive chairman and Vertex founder Josh Boger once called, “if it works, the most perfect drug I’ve ever seen.”